1.05
+0.02(+1.94%)
Currency In USD
| Previous Close | 1.03 |
| Open | 1.03 |
| Day High | 1.08 |
| Day Low | 1 |
| 52-Week High | 3.25 |
| 52-Week Low | 0.45 |
| Volume | 312,671 |
| Average Volume | 778,400 |
| Market Cap | 66.52M |
| PE | -1.15 |
| EPS | -0.91 |
| Moving Average 50 Days | 1.27 |
| Moving Average 200 Days | 1.32 |
| Change | 0.02 |
If you invested $1000 in Cue Biopharma, Inc. (CUE) since IPO date, it would be worth $91.92 as of December 05, 2024 at a share price of $1.069. Whereas If you bought $1000 worth of Cue Biopharma, Inc. (CUE) shares 5 years ago, it would be worth $94.35 as of December 05, 2024 at a share price of $1.069.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 29, 2024 9:30 PM GMT
BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the tre
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2024 1:00 PM GMT
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment
Cue Biopharma Announces Strategic Organizational Transition
GlobeNewswire Inc.
Nov 14, 2024 1:00 PM GMT
Daniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish Suri, Ph.D., president & chief scientific officer (CSO) of Cue Biopharma, to transition to principal res